Pharma is investing heavily in AI, but adoption does not guarantee impact. As experimentation gives way to accountability, commercial leaders need to determine which applications are creating measurable value and which are simply adding another layer of technology.
• Identifying where AI is generating measurable revenue, cost, productivity, or customer-experience impact across the commercial model
• Distinguishing efficiency gains and activity metrics from true incremental business value
• Understanding the data, workflow, adoption, governance, and change-management barriers that prevent successful pilots from scaling
• Building an investment framework for deciding which AI capabilities to scale, redesign, partner for, or stop funding